{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:44:15Z","timestamp":1782747855625,"version":"3.54.5"},"reference-count":20,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2-2045"],"award-info":[{"award-number":["2022-2-2045"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF150150"],"award-info":[{"award-number":["2022YFF150150"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF1501501"],"award-info":[{"award-number":["2022YFF1501501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF1501502"],"award-info":[{"award-number":["2022YFF1501502"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF1501503"],"award-info":[{"award-number":["2022YFF1501503"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF1501504"],"award-info":[{"award-number":["2022YFF1501504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF1501505"],"award-info":[{"award-number":["2022YFF1501505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC3044800"],"award-info":[{"award-number":["2024YFC3044800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0504800"],"award-info":[{"award-number":["2023ZD0504800"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0504801"],"award-info":[{"award-number":["2023ZD0504801"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0504802"],"award-info":[{"award-number":["2023ZD0504802"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0504803"],"award-info":[{"award-number":["2023ZD0504803"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0504804"],"award-info":[{"award-number":["2023ZD0504804"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425101"],"award-info":[{"award-number":["82425101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z231100004823036"],"award-info":[{"award-number":["Z231100004823036"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2025,8,19]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although previous evidence generally agreed on the short-term dual antiplatelet therapy (DAPT) for mild stroke or transient ischaemic attack (TIA), there is no consensus on the optimal threshold for stroke severity and initiation timing of DAPT. We conducted an updated meta-analysis of randomised controlled trials to evaluate early DAPT versus single therapy in mild stroke or TIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed double-blind and randomised controlled trials up to October 2024 evaluating DAPT versus monotherapy for acute mild, non-cardioembolic ischaemic stroke (National Institute of Health Stroke Scale; NIHSS\u22645) or TIA within 72 hours of ictus. Random effects models generated risk ratio (RR) with 95% CIs for outcomes including stroke, composite vascular events, ischaemic stroke, major bleeding, haemorrhagic stroke and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pooled data from five trials (n=27\u2009559) demonstrated that DAPT versus monotherapy lowered the risk of stroke recurrence (RR, 0.77; 95%\u2009CI 0.70 to 0.83), composite vascular events (RR, 0.75; 95%\u2009CI 0.68 to 0.83) and ischaemic stroke (RR, 0.74; 95%\u2009CI 0.68 to 0.81). However, DAPT increased the risk of major bleeding (RR, 2.19; 95%\u2009CI 1.38 to 3.49) and haemorrhagic stroke (RR, 2.08; 95%\u2009CI 1.13 to 3.82), with no significant increase in the risk of all-cause mortality (RR, 1.28; 95%\u2009CI 0.95 to 1.71).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For acute mild stroke (NIHSS \u22645) or patients with TIA within 72 hours of ictus, early DAPT initiation demonstrates net clinical benefit through reducing ischaemic events, despite an increase in bleeding complications, without affecting mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2025-004143","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:55:13Z","timestamp":1758646513000},"page":"267-274","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Dual versus mono antiplatelet therapy within 72 hours after onset for mild ischaemic stroke or transient ischaemic attack: meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9431-9925","authenticated-orcid":false,"given":"Yingying","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3711-0216","authenticated-orcid":false,"given":"Jinghan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[{"name":"National Center for Neurological Disorders, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuesong","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3267-0039","authenticated-orcid":false,"given":"Yilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Center for Neurological Disorders, Beijing, China"},{"name":"Chinese Institute for Brain Research, Beijng, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2026062907450608000_11.3.267.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412981"},{"key":"2026062907450608000_11.3.267.2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00302-7"},{"key":"2026062907450608000_11.3.267.3","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375"},{"key":"2026062907450608000_11.3.267.4","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.2174\/1381612827666210728102459","article-title":"Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis","volume":"27","author":"Condello","year":"2021","journal-title":"Curr Pharm Des"},{"key":"2026062907450608000_11.3.267.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"2026062907450608000_11.3.267.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800410"},{"key":"2026062907450608000_11.3.267.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916870"},{"key":"2026062907450608000_11.3.267.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26867"},{"key":"2026062907450608000_11.3.267.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309137"},{"key":"2026062907450608000_11.3.267.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"2026062907450608000_11.3.267.11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jfma.2021.08.006","article-title":"P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"2026062907450608000_11.3.267.12","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/STR.0000000000000377","article-title":"Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack","volume":"52","author":"Brown","year":"2021","journal-title":"Stroke"},{"key":"2026062907450608000_11.3.267.13","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/CIRCULATIONAHA.121.053782","article-title":"Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials","volume":"143","author":"Trifan","year":"2021","journal-title":"Circulation"},{"key":"2026062907450608000_11.3.267.14","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2018-000168"},{"key":"2026062907450608000_11.3.267.15","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209845","article-title":"Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack","volume":"103","author":"Guan","year":"2024","journal-title":"Neurology (ECronicon)"},{"key":"2026062907450608000_11.3.267.16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jamaneurol.2021.2440","article-title":"Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial","volume":"78","author":"Wang","year":"2021","journal-title":"JAMA Neurol"},{"key":"2026062907450608000_11.3.267.17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2021.4514","article-title":"Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis","volume":"79","author":"Lun","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026062907450608000_11.3.267.18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31938","article-title":"Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial","volume":"7","author":"Liu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026062907450608000_11.3.267.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70250-8"},{"key":"2026062907450608000_11.3.267.20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamaneurol.2024.0146","article-title":"Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial","volume":"81","author":"Chen","year":"2024","journal-title":"JAMA Neurol"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2025-004143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:46:03Z","timestamp":1782744363000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2025-004143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,29]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/svn-2025-004143"],"URL":"https:\/\/doi.org\/10.1136\/svn-2025-004143","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}